32 results
Thumbnail

D1.327 - Genetic Analysis of Children with Suspected Immunodeficiency: Mimickers of Inborn Errors of Immunity

Thumbnail

D1.329 - Late-Childhood Diagnosis of DNA Methyltransferase 3B Deficiency-ICF1 Syndrome

Thumbnail

D1.322 - Clinical Cardiovascular Safety Assessment of Oral Deucrictibant

Thumbnail

D1.323 - Assessing Immune Responses to Conjugate Pneumococcal Vaccination in Infants with Transient and Unclassified Hypogammaglobulinemia:Insights from a Tertiary Pediatric Center

Thumbnail

D1.324 - JAK Inhibitors in the Treatment of Chronic Mucocutaneous Candidiasis in a Patient with STAT1 Gain-of-Function Mutation

Thumbnail

D1.326 - Behind The Scenes: Primary Immunodeficiencies in Pediatric Eosinophilic Gastrointestinal Diseases

Thumbnail

D1.328 - CARD11 Dominant-Negative Mutation Presenting with Early Severe Bacterial Sepsis, Viral Susceptibility, and Alopecia Totalis in a Child

Thumbnail

D1.330 - Two different clinical presentations, two same immunological features in Purin nucleoside phosporilase deficiency

Thumbnail

D1.331 - Analysis of early complement parameters and C1INH values in newborns with a positive family history of HAE-C1INH

Thumbnail

D1.333 - Digital clinical registry pilot for hereditary angioedema: standardized monthly real-world monitoring of C1 inhibitor deficiency in Serbia

Thumbnail

D1.334 - Association of Multiple Endocrinopaties with Immune Dysregulation, Allergies and Primary Immunodeficiency

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to

Thumbnail

D2.499 - Immunoregulatory Effects of Dupilumab Added to Omalizumab-Facilitated Multi-Allergen Oral Immunotherapy in the COMBINE clinical trial